Explanipedia

Routinely collected health data on 10-year genitourinary and gastrointestinal morbidity after ultra-hypofractionated versus conventionally fractionated radiotherapy for localised prostate cancer in the randomised, non-inferiority, phase 3 trial HYPO-RT-PC Open

Astrid E. Persson, Elisabeth Kjellén, Hans Garmo, Gabriel Adrian, P. Stattin , et al. · 2025

The results support the HYPO-RT-PC findings by showing similar morbidity between ultra-hypofractionated and standard radiotherapy. Excess events were estimated to 4-8%, without increased associated mortality.

Morphological heterogeneities in prostate cancer bone metastases are related to molecular subtypes and prognosis Open

Sofia Halin Bergström, Julius Semenas, Annika Nordstrand, Elin Thysell, Johan Wänman , et al. · 2025

Histopathology-validated gross tumor volume delineations of intraprostatic lesions using PSMA-positron emission tomography/multiparametric magnetic resonance imaging Open

Josefine Grefve, Karin Söderkvist, Adalsteinn Gunnlaugsson, Kristina Sandgren, Joakim Jönsson , et al. · 2024

The combined use of mpMRI or PSMA-PET/mpMRI shows promise, achieving higher DSC and lesion coverage while minimizing non-malignant tissue inclusion, in comparison to the use of a single image type with an added CTV margin.

Accuracy of gross tumour volume delineation with [68Ga]-PSMA-PET compared to histopathology for high-risk prostate cancer Open

Maryam Zarei, Elin Wallstén, Josefine Grefve, Karin Söderkvist, Adalsteinn Gunnlaugsson , et al. · 2024

Background: The delineation of intraprostatic lesions is vital for correct delivery of focal radiotherapy boost in patients with prostate cancer (PC). Errors in the delineation could translate into reduced tumour control and potentially in…

Histopathology-Validated Gtv Delineations of Intraprostatic Lesions Using Psma-Pet/Mpmri Open

Josefine Grefve, Karin Söderkvist, Adalsteinn Gunnlaugsson, Kristina Sandgren, Joakim Jönsson , et al. · 2024

The grade of individual prostate cancer lesions predicted by magnetic resonance imaging and positron emission tomography Open

Erik Nilsson, Kristina Sandgren, Josefine Grefve, Joakim Jönsson, Jan Axelsson , et al. · 2023

Histopathology-validated lesion detection rates of clinically significant prostate cancer with mpMRI, [68Ga]PSMA-11-PET and [11C]Acetate-PET Open

Kristina Sandgren, Sara Strandberg, Joakim Jönsson, Josefine Grefve, Angsana Keeratijarut Lindberg , et al. · 2023

Objective PET/CT and multiparametric MRI (mpMRI) are important diagnostic tools in clinically significant prostate cancer (csPC). The aim of this study was to compare csPC detection rates with [ 68 Ga]PSMA-11-PET (PSMA)-PET, [ 11 C]Acetate…

Investigating microRNA Profiles in Prostate Cancer Bone Metastases and Functional Effects of microRNA-23c and microRNA-4328 Open

Helena Järemo, Julius Semenas, Sofia Halin Bergström, Marie Lundholm, Elin Thysell , et al. · 2023

MicroRNAs (miRNAs) are aberrantly expressed in prostate cancer (PC), but comprehensive knowledge about their levels and function in metastatic PC is lacking. Here, we explored the differential expression of miRNA profiles during PC progres…

Effect of docetaxel added to bicalutamide in Hormone-Naïve non-metastatic prostate cancer with rising PSA, a randomized clinical trial (SPCG-14) Open

Andreas Josefsson, Åsa Jellvert, Erik Holmberg, Klaus Brasso, René Horsleben Petersen , et al. · 2023

Docetaxel improved PFS in patients starting bicalutamide due to PSA relapse after local therapy or localized disease without local therapy. Confirmatory studies of the efficacy of docetaxel in the setting of PSA-only relapse in addition to…

Table S2 from The Proteome of Prostate Cancer Bone Metastasis Reveals Heterogeneity with Prognostic Implications Open